Buscar Close Search
Page Menu

Beth A. McCormick, PhD

Research Focus - Microbial-Based Cancer Therapy

  • Advancing preclinical development of novel microbial-based anticancer therapeutic agents
  • Investigating the interplay between microbes, tumors, and the immune system
  • Developing next-generation microbial therapeutics for multidrug resistance

Representative Publication

Mercado-Lubo R, Zhang Y, Zhao L, et al. A Salmonella nanoparticle mimic overcomes multidrug resistance in tumors. Nat Commun. 2016;7:12225

Read Publication

More Publications

In the News

Getting Results…
  • UMass Chan Medical School launches Partner in Microscopy program with Leica Microsystems

    UMass Chan Medical School launches Partner in Microscopy program with Leica Microsystems

    The UMass Chan Medical School light microscopy core facility, Sanderson Center for Optical Experimentation, announced a new collaboration with Leica Microsystems.

    Read more
  • Beth McCormick and Michael Stauff named department chairs

    Beth McCormick and Michael Stauff named department chairs

    Beth A. McCormick, PhD, has been named the new chair of the Department of Microbiology & Physiological Systems (MaPS), and Michael P. Stauff, MD, has been appointed chair of the Department of Orthopedics & Physical Rehabilitation.

    Read more
  • Using the microbiome to protect against radiation exposure

    Using the microbiome to protect against radiation exposure

    Beth McCormick, PhD, and Vanni Bucci, PhD, are leading a $3 million effort to explore engineering the gut microbiome to counteract the effects of radiation exposure and total body irradiation.

    Read more
  • MD/PhD student approaches Alzheimer’s disease through gut microbiome research

    MD/PhD student approaches Alzheimer’s disease through gut microbiome research

    After college, MD/PhD student Ethan Loew was torn between practicing bench science or becoming a clinician, but his postgraduate experience in a lab and a hospital showed him how he could combine the two.

    Read more
  • New study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19

    New study of oral therapy candidate indicates positive results for patients with mild-to-moderate COVID-19

    New research by Kaleido Biosciences, Inc., and UMass Medical School’s John P. Haran, MD, PhD, and Beth McCormick, PhD, shows that the company’s microbiome metabolic therapy candidate produced positive results in patients with mild-to-moderate COVID-19.

    Read more
  • Novel therapeutic, based on UMMS microbiome discoveries and licensed by Bacainn Therapeutics, targets ulcerative colitis

    Novel therapeutic, based on UMMS microbiome discoveries and licensed by Bacainn Therapeutics, targets ulcerative colitis

    Discoveries made by Beth McCormick, PhD, and licensed by Bacainn Therapeutics, Inc. are heading to Phase I clinical trials for ulcerative colitis and other diseases associated with uncontrolled inflammation in the gut.

    Read more